Skip to content

Rapport Therapeutics, Inc. RAPP Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$103.85M-61.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$9.82M+54.0%
PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
-$24.41M-2.2%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
Biohaven logo
BiohavenBHVN

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.91B+309%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Rapport Therapeutics, Inc. (RAPP) reported comprehensive income (loss), net of tax, attributable to parent of -$20.91M in Q1 2026.
How has Rapport Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Rapport Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 11.5% year-over-year, from -$23.64M to -$20.91M.
What is the long-term trend for Rapport Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 78.2% compound annual growth rate (CAGR), from -$34.78M to -$110.42M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources during the period, encompassing both net income and other comprehensive income items. It provides a more holistic view of financial performance by including unrealized gains and losses that are excluded from the traditional income statement. Analysts use this to assess the total impact of market fluctuations and accounting adjustments on the company's overall net worth.